Sharp's Emissions Reduction Targets Validated by Science Based Targets Initiative

Sharp recently announced its near-term and long-term greenhouse gas (GHG) emission reduction targets have been officially validated by the Science Based Targets initiative (SBTi). This validation marks a significant step in the company’s journey to reduce its environmental impact and to play its part in a more sustainable future for the pharmaceutical industry.

The SBTi, a global body recognised as the leader in climate-related reporting and target-setting frameworks, aligns directly with climate science to establish emission reduction targets and actions required to limit the increase in global temperatures in line with the goals of the Paris Agreement – to limit global warming to 1.5°C above pre-industrial levels. This validation by SBTi underscores Sharp’s structured approach to sustainability and its commitment to delivering measurable progress in managing its climate impact.

“Validation of our science-based targets is a significant milestone for us that further embeds environmental responsibility into Sharp’s long-term strategy,” said Kevin Orfan, President & CEO of Sharp. “These targets represent a significant, enduring commitment to our planet and to all our stakeholders. By working towards these goals, we will build a more resilient and sustainable business and contribute positively to the well-being of our communities, our employees, and the broader industry for years to come.”

Sharp’s validated targets include:

• Near-term Target: Sharp commits to reducing absolute Scope 1 and 2 GHG emissions by 54.6% and scope 3 by 32.5% by 2033, from a 2023 baseline.
• Long-term Target: Sharp commits to reducing absolute Scope 1, 2, and 3 GHG emissions by 90% by 2050, from a 2023 baseline, working towards achieving Net Zero emissions by 2050.

“Having established a robust understanding and reporting of our current emissions, including our Scope 3 emissions, we now have a clear, scientifically backed target to significant reductions,” commented Hywel Woolf, Sharp’s Global Sustainability Manager. “This validation provides us with concrete objectives that will guide our operational decisions, from energy consumption and resource efficiency within our facilities. We look forward to collaborating deeply with our clients and our supply chain partners to achieve these goals.”

Sharp has begun to develop a detailed climate transition plan that will deliver on these verified targets, while also supporting the delivery of clients’ own climate targets. The company has already implemented initiatives such as supplying all facilities with renewable electricity and achieving zero waste disposal to landfill and will now focus on accelerating these efforts, prioritizing key areas such as optimizing energy consumption and waste management, enhancing supply chain efficiency, and engaging with its broader network to drive collective action. Sharp’s continued participation in the Alliance to Zero, a supply chain alliance co-founded in 2021 to enable the transition to Net Zero pharma products, demonstrates this collaborative approach.

This SBTi validation also addresses the increasing demand from clients, employees, owners, and supply chain partners for verified sustainability progress. By aligning its operations with climate science, Sharp is working towards a more resilient and sustainable business model, contributing to a better future for the pharmaceutical industry and beyond.

For further information on Sharp’s sustainability initiatives, please visit: https://www.sharpservices.com/about-us/sustainability-esg/  and read our recent announcements: https://www.sharpservices.com/about-us/news/

Sharp is a leader in pharmaceutical packaging, clinical trial supply services & small-scale sterile manufacturing, with a heritage spanning more than 70 years. We partner with pharmaceutical and biotechnology clients, offering solutions and support from phase I trials all the way through to commercial launch and lifecycle management. Together, our 2,200+ strong team leverage the capabilities in state-of-the-art GMP facilities in the US, UK, Belgium, and the Netherlands.